Mounjaro vs Ozempic — Which One Works Better? - Beyond the Scale: The Hidden Data

Host Ben Synth examines the SURMOUNT-5 trial's overlooked findings beyond weight loss: tirzepatide versus semaglutide's impact on cardiovascular risk, quality of life, and long-term health outcomes. We discuss post-hoc analysis published in the European Heart Journal Open suggesting potential population-level differences in predicted heart attack and stroke prevention between these obesity medications.Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTVThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.